Literature DB >> 33187944

Osteonecrosis of the jaw associated with imatinib therapy in myeloproliferative neoplasm: a rare case report.

Lokendra Gupta1, Kanchan Dholam2, Yogesh Janghel3, Sandeep V Gurav4.   

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) is a relatively infrequent but very well-known adverse effect of bisphosphonates. This rare complication of bisphosphonates is rarest with the use of certain drugs. Tyrosine kinase inhibitors (TKIs), particularly used in renal cell carcinoma or gastrointestinal tumors as a chemotherapeutic agent, can precipitate this particular medical condition of bone when it is associated with either radiation or bisphosphonates, though, monodrug therapy with TKIs rarely causes MRONJ. This article describes a rare case of necrosis of the jawbone in a patient with a myeloproliferative neoplasm who was receiving the TKI imatinib and had no history of bisphosphonate or radiation therapy to head and neck region.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33187944     DOI: 10.1016/j.oooo.2020.10.005

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol


  2 in total

Review 1.  The impact of sex steroids on osteonecrosis of the jaw.

Authors:  Ranhee Kim; Sung Woo Kim; Hoon Kim; Seung-Yup Ku
Journal:  Osteoporos Sarcopenia       Date:  2022-06-17

Review 2.  Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates.

Authors:  L Lorusso; L Pieruzzi; M Gabriele; M Nisi; D Viola; E Molinaro; V Bottici; R Elisei; L Agate
Journal:  J Endocrinol Invest       Date:  2021-07-21       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.